Navigation Links
New type of vaccines deliver stronger and faster immune response
Date:11/24/2008

A new vaccine principle is being developed by scientists at the University of Copenhagen which if it works to its full expected potential could help to save millions of lives and revolutionise current vaccine technology. The 'InVacc' platform, as it is known, represents an advance on the original DNA vaccines and generates new vaccines with greatly enhanced properties. The platform consists of a chain of amino acids attached to a gene of the virus being vaccinated against. This genetic cocktail is then inserted into an incapacitated flu-like virus such as the adenovirus and injected into the body, where it triggers a broader and more aggressive immune response, enabling the immune system to quickly seek out and destroy the disease when it invades.

"We are excited to be working on the vaccine technology", says Associate Professor Jan Pravsgaard, the lead scientist behind the project. "The platform has proved very effective in our recent tests and could have enormous potential. In principle, vaccines of this type could be used to inoculate against a range of deadly viruses, bacteria and other disease-causing agents and even be used to cure certain cancers once they take hold."

Tests of the vaccine platform on mice so far look extremely promising with the scientists able to provide 100% protection against different, lethal strains of flu given to the test animals.

The scientists also believe that the new technology will be effective despite the ability of different viruses and bacteria to constantly mutate and develop resistance.

Key benefits of the new technology:

  • The new platform delivers a broad and very powerful immune re-sponse, enabling the immune system to defeat invading pathogens.
  • Unlike many vaccines, InVacc activates the CD4+ T cells of the immune system, which govern and coordinate the other immune system attack cells. For reasons not yet fully understood, activating the CD4+ cells enhances the response of the associated attack cells (producing large numbers of CD8+ cells) and is an important reason why the platform is able to deliver such a strong immune response.
  • InVacc provides rapid protection. In animal tests, complete protection was achieved in less than 3 days after a single vaccination. This could have significant implications for the handling of epidemics, quickly halting infection rates and preventing major outbreaks.

The Scandinavian company Novo A/S and the Novo Nordisk Foundation have such faith in the new technology that they have already invested funds to create a strategic plan for development and use of the platform. "The grants awarded through our Novo Seeds programme are only for very select projects that show outstanding promise, both scientifically and commercially, explains Novo Seeds Investment Director, Stephen Christgau." "The InVacc platform is definitely one of those. Our grants will help the team to develop and commercialise their groundbreaking research and validate the advantages of the vaccine platform against competing technologies".

Peter Holst, PhD, from the research team, (together with the Technical Transfer Unit at the University of Copenhagen), are currently also seeking backing from international funds to take the project to its next phase of development and ultimately into clinical trials.


'/>"/>

Contact: sandra szivos
sasz@sund.ku.dk
0045-353-6921
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Syracuse University partners with Serum Institute of India to develop vaccines for children
2. Prostate cancer vaccines more effective with hormone therapy
3. From foe to friend: Researchers use salmonella as a way to administer vaccines in the body
4. VaxInnate to discuss seasonal and pandemic flu vaccines during BIO 2008 this week
5. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
6. Depression during pregnancy can double risk of preterm delivery
7. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
8. RNA molecules, delivery system improve vaccine responses, effectiveness
9. Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency
10. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
11. ID Solutions Achieves Full-Production Delivery and Payment for Fingerprint Processing Software for TWIC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... , ... August 11, 2017 , ... Algenist continues to ... formulation unlocking collagen like never before. , Collagen is the key structural element ... market with Liquid Collagen™, which include: , First to ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... London UK (PRWEB) , ... August 10, 2017 , ... ... host a new educational webinar to demonstrate how Good Clinical Practice (GCP) ... and site documents. In addition the webinar will discuss the importance of GCP compliance, ...
(Date:8/10/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic ... or the "Company"), today reported operational highlights and financial ... 30, 2017. Revenue from biopreservation media product ... the second quarter of 2017, an increase of 29% ...
Breaking Biology Technology: